ReviewAphasiology2012
Dopaminergic therapy in aphasia.
Review in Aphasiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Striatal dopaminergic patterns and clinical features in frontotemporal dementia.Brain communications · 2025Article
- Relationships of the arcuate fasciculus and nigrostriatal tract with language ability in intracerebral hemorrhage using a diffusion tensor imaging.Scientific reports · 2023Article
- Supporting Post-Stroke Language and Cognition with Pharmacotherapy: Tools for Each Phase of Care.Current neurology and neuroscience reports · 2023Review
- Possible Effects of Acupuncture in Poststroke Aphasia.Behavioural neurology · 2023Review
- Effects of Acupuncture-Related Therapies in the Rehabilitation of Patients with Post-Stroke Aphasia-A Network Meta-Analysis of Randomized Controlled Trials.Brain sciences · 2022Review
- Review
- Better language through chemistry: Augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia.Handbook of clinical neurology · 2022Review
- Novel Advances to Post-Stroke Aphasia Pharmacology and Rehabilitation.Journal of clinical medicine · 2021Review
- Case Report: Improving Verbal Retrieval Deficits With High Definition Transcranial Direct Current Stimulation Targeting the Pre-Supplementary Motor Area in a Patient With Chronic Traumatic Brain Injury.Frontiers in neurology · 2021Article
- Language as a Threat: Multimodal Evaluation and Interventions for Overwhelming Linguistic Anxiety in Severe Aphasia.Frontiers in psychology · 2019Article
- When two are better than one: Bilateral mesial temporal lobe contributions associated with better vocabulary skills in children and adolescents.Brain and language · 2018Article
- The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery.Frontiers in synaptic neuroscience · 2018Review
- Reversible global aphasia as a side effect of quetiapine: a case report and literature review.Neuropsychiatric disease and treatment · 2017Article
- Recent advances in the treatment of post-stroke aphasia.Neural regeneration research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe dopaminergic system is involved in a wide range of cognitive functions including motor control, reward, memory, attention, problem-solving and learning. This has stimulated interest in investigating the potential of dopaminergic drugs as cognitive enhancers in aphasic patients.
aimTo discuss the evidence for the use of dopaminergic agents in patients with aphasia. Levodopa (L-dopa) and the dopamine agonist bromocriptine are the two drugs that have been trialled to date. We discuss, in some detail, the 15 studies that have been published on this topic from the first case report in 1988 to the present (2012), and assess the evidence from each. MAIN CONTRIBUTION: In addition to summarising the effectiveness of the drugs that have been tried, we examine the possible cognitive mechanisms by which dopaminergic drugs may act on language function and aphasia recovery. Given the wide range of dopaminergic drugs, it is surprising that such a narrow range has been trialled in aphasic patients. Important lessons are to be learned from published studies and we discuss optimal trial designs to help guide future work.
conclusionsThe evidence for the efficacy of dopaminergic agents in aphasia therapy is mixed. Further trials with better tolerated agents are required. Optimal trial designs with appropriate control groups or blocks should be used. The mechanism of action is unclear, but at the cognitive level the evidence points towards either (re)learning of word-forms or their improved retrieval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.